Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Black Diamond Therapeutic...

    NASDAQ: BDTX · Real-Time Price · USD
    2.33
    -0.06 (-2.51%)
    At close: Jun 17, 2025, 1:58 PM

    Black Diamond Therapeutics Statistics

    Share Statistics

    Black Diamond Therapeutics has 56.86M shares outstanding. The number of shares has increased by 0.73% in one year.

    Shares Outstanding

    n/a
    		 56.86M

    Shares Change (YoY)

    n/a
    		 0.73%

    Shares Change (QoQ)

    n/a
    		 0.14%

    Owned by Institutions (%)

    n/a
    		 84.77%

    Shares Floating

    n/a
    		 43.3M

    Failed to Deliver (FTD) Shares

    n/a
    		 9,643

    FTD / Avg. Volume

    n/a
    		 0.27%

    Short Selling Information

    The latest short interest is 7.57M, so 13.31% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 7.57M

    Short % of Shares Out

    n/a
    		 13.31%

    Short % of Float

    n/a
    		 19.13%

    Short Ratio (days to cover)

    n/a
    		 8.01

    Valuation Ratios

    The PE ratio is -1.69 and the forward PE ratio is -2.25. Black Diamond Therapeutics's PEG ratio is 0.05.

    PE Ratio

    n/a
    		 -1.69

    Forward PE

    n/a
    		 -2.25

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 1.2

    PB Ratio

    n/a
    		 1.41

    P/FCF Ratio

    n/a
    		 -1.89

    PEG Ratio

    n/a
    		 0.05
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Black Diamond Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.92, with a Debt / Equity ratio of 0.27.

    Current Ratio

    n/a
    		 4.92

    Quick Ratio

    n/a
    		 4.92

    Debt / Equity

    n/a
    		 0.27

    Debt / EBITDA

    n/a
    		 -0.32

    Debt / FCF

    n/a
    		 -0.36

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-2,903,166.67

    Employee Count

    n/a
    		 24

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -56.12% in the last 52 weeks. The beta is 2.71, so Black Diamond Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.71

    52-Week Price Change

    n/a
    		 -56.12%

    50-Day Moving Average

    n/a
    		 1.87

    200-Day Moving Average

    n/a
    		 2.64

    Relative Strength Index (RSI)

    n/a
    		 58.91

    Average Volume (20 Days)

    n/a
    		 3,520,319

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -78.78M

    Net Income

    n/a
    		 -69.68M

    EBITDA

    n/a
    		 -69.33M

    EBIT

    n/a
    		 -69.68M

    Earnings Per Share (EPS)

    n/a
    		 -1.27
    Full Income Statement

    Balance Sheet

    The company has 36.44M in cash and 22.19M in debt, giving a net cash position of 14.25M.

    Cash & Cash Equivalents

    n/a
    		 36.44M

    Total Debt

    n/a
    		 22.19M

    Net Cash

    n/a
    		 14.25M

    Retained Earnings

    n/a
    		 -487.11M

    Total Assets

    n/a
    		 176.25M

    Working Capital

    n/a
    		 138.83M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -62.3M and capital expenditures 0, giving a free cash flow of -62.3M.

    Operating Cash Flow

    n/a
    		 -62.3M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -62.3M

    FCF Per Share

    n/a
    		 -1.13
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    BDTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for BDTX is $15, which is 525% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $15

    Price Target Difference

    n/a
    		 525%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 0.38

    Piotroski F-Score

    n/a
    		 7

    Add to Watchlist